New, user-friendly analytical systems provide high-throughput comprehensive characterization and quantitation of small and large molecules.
The next-generation Thermo Scientific Vanquish Duo ultra-high-performance liquid chromatography (UHPLC) systems, which can maximize throughput and return on investment (ROI) while providing scientists with a robust and comprehensive understanding of their samples, provides the tools to address the analytical complexity of new and emerging pharmaceuticals and biopharmaceuticals. These new systems are suited to streamline workflows and help reduce cost per sample, according to the company.
"The increasing demand being placed on the pharmaceutical and biopharmaceutical industry to deliver safe and effective medicines that meet regulatory standards is presenting a unique set of analytical challenges," said Fabrizio Moltoni, vice president and general manager, HPLC, chromatography and mass spectrometry, Thermo Fisher Scientific, in a company press release. "The Vanquish Duo UHPLC systems provide a high-throughput and robust solution required to enable full characterization of small and large molecules in a manner that creates confidence and quality, while helping to protect customers' investment."
Each system enables scientists to meet different analytical and resource challenges:
The Vanquish Duo UHPLC systems' ability to analyze is maximized through integration with Thermo Scientific Chromeleon Chromatography Data System (CDS) software, which streamlines workflows through software tools targeting simplified method transfer and independent control of two flow paths in one analytical system.
The systems made their debut at Pittcon 2018 in Orlando, FL, on Feb. 26-Mar. 1, 2018.
Source: Thermo Fisher Scientific